Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000172 · ClinicalTrials.gov registry record · Phase 3

Evaluation of Galantamine in the Treatment of Alzheimer's Disease

A Phase 3 study of Alzheimer Disease, sponsored by Janssen.

Completed
Registry status
Phase 3
Development phase
20
Study locations

NCT00000172 is a Phase 3 study of Alzheimer Disease that has completed, run by Janssen. The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000172, a Phase 3 study of Alzheimer Disease, has completed, sponsored by Janssen.

COMPLETED
Registry status
Phase 3
Development phase
20
Study locations

Study Summary

Galantamine is an experimental drug being evaluated in the United States for the treatment of Alzheimer's disease. Results from previous clinical trials suggest that galantamine may improve cognitive performance in individuals with Alzheimer's disease. It is not a cure for Alzheimer's disease. Nerve cells in the brain responsible for memory and cognitive function communicate using a chemical called acetylcholine. Research has shown that deterioration of cells that produce acetylcholine in the brain affects thought processes. Galantamine is thought to work in two ways to increase the amount of acetylcholine available in the brain. It inhibits an enzyme that breaks down acetylcholine and it also stimulates the nicotinic receptors in the brain to release more acetylcholine.

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG Galantamine

Study Locations (20)

California

  • East Bay Neurology - Berkeley
  • University of Southern California - Los Angeles
  • N. County Neurology Assoc. - Oceanside
  • University of California Irvine Medical Center - Orange
  • Pacific Research Network (PRN) - San Diego
  • Affiliated Research Institute - San Diego
  • INC - San Diego

Florida

  • Ocala Neurodiagnostic Center - Ocala
  • Psychiatric Institute of Florida - Orlando
  • Neurological Research Institute of Sarasota, PA - Sarasota
  • Suncoast Neuroscience Associates, Inc. - St. Petersburg
  • Premiere Research Institute - West Palm Beach

Connecticut

  • Geriatric and Adult Psychiatry - Hamden
  • Yale University, School of Medicine - New Haven

Illinois

  • Chicago Center for Clinical Research - Chicago
  • OSF Center for Senior Health - Peoria

Alabama

  • University of Alabama, Birmingham - Birmingham

Arizona

  • James L. Frey, M.D., Ltd. - Scottsdale

Colorado

  • The Denver Center for Medical Research - Denver

Indiana

  • Indiana Alzheimer's University Clinic - Indianapolis

Trial Details

FieldValue
Phase Phase 3

Sponsor

Janssen

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00000172

The ClinicalTrials.gov registry entry for NCT00000172 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Janssen, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Galantamine is the first listed.

NCT00000172 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00000172 about?

NCT00000172 is a clinical study titled "Evaluation of Galantamine in the Treatment of Alzheimer's Disease". Galantamine is an experimental drug being evaluated in the United States for the treatment of Alzheimer's disease. Results from previous clinical trials suggest that galantamine may improve cognitive performance in individuals with Alzheimer's disease. It is not a cure for Alzheimer's disease. Nerve...

What is the current status of trial NCT00000172?

This trial is currently completed. It is a Phase 3 study.

What conditions does trial NCT00000172 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT00000172?

The interventions under investigation include: Galantamine (DRUG).

Who is sponsoring clinical trial NCT00000172?

This trial is sponsored by Janssen, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000172 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.